Penumbra, Inc. — FY2016 Form 10-K
Business context and reporting period. Penumbra designs, manufactures and sells interventional medical devices for neurovascular and peripheral vascular procedures. This 10-K covers the fiscal year ended December 31, 2016; quarterly figures below refer to the quarter ended December 31, 2016.
Financial performance
| Metric | FY2016 | FY2015 |
|---|---|---|
| Revenue | $263.3 million | $186.1 million |
| Gross profit / margin | $170.8 million / 64.9% | $124.1 million / 66.7% |
| Operating income (loss) / margin | $(1.4) million / (0.5)% | $4.2 million / 2.2% |
| Income (loss) before taxes | $(0.9) million | $4.0 million |
| Income tax benefit (expense) | $15.7 million benefit | $(1.7) million expense |
| Net income | $14.8 million | $2.4 million |
| Net cash from (used in) operating activities | $(12.8) million | $(20.7) million |
Revenue increased 41.5%. Neuro revenue rose 31.2% to $185.5 million; peripheral vascular revenue rose 74.1% to $77.8 million. U.S. sales were $176.1 million and international sales were $87.2 million, or 33.1% of revenue. The Japanese distributor accounted for approximately 11.5% of revenue.
For Q4 2016, revenue was $73.1 million and gross profit was $46.6 million. The quarter reported a pretax loss of $1.5 million and net loss of $2.4 million.
Liquidity, debt and cash flow
- At year-end, cash and cash equivalents were $13.2 million, marketable investments $115.5 million, and working capital $228.0 million. Current assets were $263.8 million and current liabilities $35.8 million.
- Operating cash use improved from $20.7 million to $12.8 million, but remained negative. Inventory increased $19.7 million and accounts receivable increased $14.6 million, contributing to operating cash outflow.
- Capital expenditures were $13.6 million. Cash declined by $6.3 million during the year to $13.2 million.
- No debt was reported at year-end. The company’s former credit facility was terminated in 2014.
Material changes and unusual items
- Gross margin declined 1.8 percentage points, primarily due to product and geographic mix, hiring and training costs, and lower initial yields on new products.
- Operating expenses rose 43.6% to $172.2 million. SG&A increased 45.6%, reflecting headcount and growth-related costs; R&D increased 32.4% to $23.9 million.
- Net income was substantially affected by early adoption of ASU 2016-09: Penumbra recognized $17.2 million of excess stock-compensation tax benefits in its income tax benefit, including a $3.3 million discrete benefit from carrying back 2016 losses. The reported 1,805% effective tax rate reflects this unusual tax accounting and is not a recurring operating margin measure.
- Inventory write-downs were $2.7 million, versus $1.2 million in 2015.
Outlook, commentary and risks
Management expects growth rates in neuro and peripheral vascular markets to moderate from recent rapid levels. It expects continued investment in product development, clinical work, sales capacity, manufacturing and international expansion; no numerical revenue or earnings guidance is provided. Management believes existing liquidity is sufficient for at least the next 12 months, while noting that additional financing may be considered.
- Key exposures include medical-device regulatory and reimbursement requirements, clinical evidence and product adoption, competition, product liability, intellectual-property disputes, reliance on a single Alameda manufacturing campus and certain limited-source suppliers, inventory needs, and unhedged foreign-currency exposure.
- A product-liability case involving Penumbra Coil 400 was in discovery. Plaintiff’s counsel had suggested potential damages of $35 million, substantially above insurance coverage; the company said it could not assess the merits and intended to defend the case. The hospital defendant was dismissed in July 2016.
- The FDA issued two Form 483s following 2015 inspections concerning clinical-site monitoring and CAPA effectiveness checks. Penumbra reported timely responses and corrective actions; the FDA said the responses appeared adequate, subject to possible future verification.
- Management and the auditor reported effective disclosure controls and internal control over financial reporting as of year-end; the auditor issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- How much of FY2016 net income and EPS depended on the non-recurring stock-compensation tax benefit, and what normalized earnings may be.
- Whether sales growth can continue as management expects slower market growth, and whether margins can recover as product mix and launch costs change.
- Cash conversion, inventory and receivables growth, and the funding required for continued expansion and capital spending.
- Developments in the Coil 400 litigation, potential exposure beyond insurance, and any product-safety or regulatory updates.
- Exposure to the Japanese distributor, international reimbursement and currency movements, and manufacturing or supplier concentration.